We founded InvestAcure because Alzheimer’s must be cured!
Our vision is to see a world where drug companies are owned by millions of spare change investors committed to curing Alzheimer's.
We believe that by bringing together a vast community of cure motivated spare
change investors, brilliant scientists and well-managed companies, we can ensure
that cutting edge scientific discoveries are turned into a lifesaving cure for
Social entrepreneur who built RAJE, a large educational non-profit and had the idea for InvestAcure when his daughter was battling cancer.
Chief Investment Officer
NGN Capital, Co-founder & Managing General Partner, voted top pharmaceutical analyst by Institutional Investor Magazine, Wall Street Analyst Hall of Fame, MBA, Harvard Business School.
David Weild IV
31 years Wall Street investment banking and equity capital markets leadership, Founder, Chairman & CEO of Weild & Co., Former Vice Chairman of the NASDAQ, known as "The father of the JOBS Act", served as President & Head of Corporate Finance at Prudential.
Chief Experience Officer - Head of UI/UX Design
15 years Gamification and UI/UX design leadership for world's leading brands, including Google, LEGO, eBay, Huawei, and Volkswagen/Porsche.
EVP of Development, InvestAcure Foundation
Experienced nonprofit & social impact executive, Founder of Nextdor, a social impact startup accelerator & Bizrael, a leading nonprofit connecting US & Israeli pharmaceutical & tech startups.
Lawrence Pine COO
COO Worked with Max as the COO of RAJE and joined him in co-founding the new company. MBA & IT background.
Director of Corporate Communications & Events
5 years communications & development, Communication Officer @ Smith & Lewis Global, BA Political Science & Government Smith College.
Scientific Advisory Board
George Perry, Ph.D Scientific Advisor
Editor-in-Chief of Journal of Alzheimer's, Dean UT-San Antonio, one of the top most-cited scientists in Neuroscience.
Pierre Tariot, MD
Director of the Banner Alzheimer’s Institute. Over 350 scientific papers, including several leading to FDA approval of treatments for Alzheimer's.
Hugo Geerts, Ph.D Scientific Advisor
CSO of In Silico Biosciences, headed Johnson & Johnson Alzheimer’s research and developed one of only 5 approved Alzheimer’s drugs.
Adeboye Adejare, Ph.D Scientific Advisor
NIH and Alzheimer’s Association national panels. Over 50 publications, 5 patents, and more than 100 presentations at conferences.
J. Thomas Vaughan, Ph.D Scientific Advisor
Columbia University – Director of MR Research – 45 patents – pioneer in development of MRI technology for diagnosis of Alzheimer’s.
Lon Schneider, Ph.D
Director of USC State of California Alzheimer’s Disease Center and the National Institute on Aging Alzheimer’s Disease Research Center. Editor-in-chief of Alzheimer’s & Dementia: Translational Research and Clinical Interventions.
Douglas J MacNeil, Ph.D
A leading expert in early-stage drug discovery directed Exploratory & Translational Sciences at Merck, scientific board of Alzheimer's Drug Discovery Foundation, 144 research publications.
Paul Newhouse, MDScientific Advisor
Director at Center for Cognitive Medicine, Vanderbilt University. Lead consultant to pharmaceutical & biotechnology companies in the US and abroad on central nervous system drug development, clinical trial design for dementia & depression, & clinical nicotinic pharmacology.
Business Advisory Board
Julie Fleming, Purple Sherpa CEO & Founder Advisor
Julie is a former patent litigator with a science background, and founder of a law-firm business consultancy. Julie’s father is a retired lawyer with Alzheimer’s and vascular dementia.
Beau Mann, Sober Grid CEO & Founder
Beau is an avid entrepreneur – starting and advising several digital companies. Member of the Forbes Technology Council and has been featured in the NY Times, Inc. Magazine, Entrepreneur Magazine, just to name a few.
Alex Geis Lead Tech Advisor
Founded 21Productions, licensed software to leading universities, CTO at TruOptik
Heidi V. Picket
Assistant Dean of MIT Sloan Master of Finance Program - a recognized expert on corporate development, business strategy, and global operations, served as Senior Managing Director at State Street Global Markets, President of the Verrill Foundation.
Peter McCrea, Cavendish Foundation, President
Expert in Venture philanthropy & Impact investment. As VP of Development at American Endowment Foundation, increased total assets from $480 mil to $2 bil, served on Board of Directors of Morgan Stanley Global Impact Funding Trust & as EVP at Institute for Nonprofit Excellence.
Sign up today and find out how you can help build a world without Alzheimer’s.
Disclosure: The investacure.com website is owned and operated by InvestAcure, PBC. Investacure PBC does not provide investment advice; any investment advice is provided by InvestAcure, LLC an SEC-registered investment advisor, which is a wholly owned subsidiary of InvestAcure, PBC.